Data updated: Jun 28, 2026
IPLEX (mecasermin rinfabate recombinant) · INSMED
Endocrine
Approved 2005-12-12
1
Indication
--
Phase 3 Trials
1
Priority Reviews
20
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2005-12-12
- Patent Cliff
- 2012
- Routes
- SUBCUTANEOUS
- Dosage Forms
- INJECTABLE
IPLEX Approval History
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2005 to 2007
Dec 2005 ORIGINAL Priority
Update · Type 1 - New Molecular Entity and Type 4 - New Combination
What IPLEX Treats
1 FDA approvalsOriginally approved for its first indication in 2005 .
- Other (1)
INSMED's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
IPLEX FDA Label Details
Track IPLEX with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.